One-Year Data from Zimmer Biomet mymobility Clinical Study

Zimmer Biomet announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of  the mymobility® with Apple Watch remote care management platform. The data show that using mymobility with Apple Watch following primary knee replacement can effectively guide rehabilitation, demonstrate similar outcomes to traditional care models, and significantly reduce the number of outpatient physical therapy visits. In addition, use of mymobility with Apple Watch was associated with significantly fewer surgery-related emergency department visits.

The data evaluated 401 patients who underwent total or partial knee replacement. Patients were randomized to a mymobility with Apple Watch exercise and educational platform group, or a control group who received traditional care. Among the outcomes assessed at the one-year follow-up were Knee injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR), PT visits, readmissions and emergency department/urgent care visits.

Key data findings include:

• Patients in the mymobility with Apple Watch group who did not require adjunct physical therapy had significantly higher KOOS, JR scores compared to controls at one year post-op.
• Significantly fewer patients in the mymobility with Apple Watch group required post-operative physical therapy.
• Overall KOOS, JR scores were similar between control group and mymobility with Apple Watch group at one year.
• The change in KOOS, JR scores from pre-op levels were similar at one year for the control group and the mymobility with Apple Watch group.
• Significantly fewer patients in the mymobility with Apple Watch group utilized surgery-related emergency department/urgent care compared to the control group.
• Similar rates of readmission were observed between the mymobility with Apple Watch group and the control group.

“The past two years have brought into greater focus the benefits and conveniences of remote care, which is rapidly becoming the new normal for many people around the world,” said Nitin Goyal, M.D., Chief Science, Technology and Innovation Officer at Zimmer Biomet. “By undertaking a large randomized controlled trial comparing outcomes associated with a smartphone-based remote care model versus a traditional care model, Zimmer Biomet is proud to be at the forefront of efforts to validate platforms, like mymobility with Apple Watch, as a viable alternative to the standard of care.”

Source: Zimmer Biomet